The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.

Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio of two proteins, pTau217 and ß-Amyloid 1-42, which are implicated in ...